Gabapentin Capsule
Product Images NDC 71335-0220

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-0220). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Capsules Usp 1)

A mathematical formula for calculating creatinine clearance (CLCr), including variables for age, weight, and serum creatinine, with an adjustment factor for female patients. The formula is not specific to Gabapentin but is often related to renal function assessment.*

FDA Label Image

Chem Structure (Gabapentin Capsules Usp 2)

Chemical structure of the active ingredient gabapentin, showing a cyclohexane ring attached to a carbon bearing an amino group and an acetic acid group.*

FDA Label Image

10 (Gabapentin Capsules Usp 3)

A line graph depicting mean pain score over an 8-week period comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks including baseline, and the y-axis shows mean pain score from 0 to 10. The graph distinguishes a 4-week dose titration period and a subsequent 4-week fixed dose period, with Gabapentin showing a greater reduction in pain score than placebo.*

FDA Label Image

10 (Gabapentin Capsules Usp 4)

A line graph showing mean pain score changes over 7 weeks for placebo and two Gabapentin doses (1800 mg/day and 2400 mg/day). The x-axis represents weeks, and the y-axis represents mean pain score. The study includes a 3-week dose titration period followed by a 4-week fixed dose period, with Gabapentin groups showing a decrease in pain scores compared to placebo.*

FDA Label Image

10 (Gabapentin Capsules Usp 5)

Bar chart illustrating the proportion of responders (patients with ≥ 50% reduction in pain score) at endpoint in controlled postherpetic neuralgia (PHN) studies. Data compare placebo (PBO) versus Gabapentin (GBP) at different dosages (1800 mg, 2400 mg, and 3600 mg) across two separate studies, showing higher responder rates with Gabapentin.*

FDA Label Image

Figure 4 (Gabapentin Capsules Usp 6)

A scatter plot comparing percentage difference against daily dose (mg) for three studies labeled a, b, and c. The x-axis is daily dose ranging from 600 to 1800 mg, and the y-axis shows difference (%) from 2 to 22. Data points show increasing difference with dose for each study, with study a marked by solid black squares, study b by gray squares, and study c by white squares.*

FDA Label Image

Label (Lbl713350220)

Gabapentin Capsules, USP 300 mg label by Bryant Ranch Prepack. The label shows the NDC 71335-220-01, includes a barcode, storage instructions (20° to 25°C), and indicates the package contains 30 capsules. The label also includes cautionary text stating the medication may cause dizziness and a QR code with additional product data.*

FDA Label Image

Label (Lbl7133502202)

Gabapentin 300 mg capsule label, packaged by Bryant Ranch Prepack. The label includes a comparison to Neurontin 300 mg capsule and manufacturer Amneal Pharmaceuticals Pvt. Ltd. It specifies storage at room temperature (20°-25°C or 68°-77°F) and contains warnings about dizziness and keeping drugs out of reach of children. The package contains 30 capsules and is marked Rx only with NDC 71335-0220.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.